Table of Contents
Journal of Neurodegenerative Diseases
Volume 2014 (2014), Article ID 435164, 10 pages
http://dx.doi.org/10.1155/2014/435164
Review Article

Multidisciplinary Interventions in Motor Neuron Disease

Internal Medicine Department, University of Calabar, Calabar, Cross River State 540242, Nigeria

Received 20 June 2014; Revised 29 September 2014; Accepted 28 October 2014; Published 18 November 2014

Academic Editor: Anabela C. Pinto

Copyright © 2014 U. E. Williams et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Logroscino, B. J. Traynor, O. Hardiman et al., “Descriptive epidemiology of amyotrophic lateral sclerosis: new evidence and unsolved issues,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 1, pp. 6–11, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. MNDA, Research Strategy 2006–2012, Motor Neuron Disease Association, Northampton, UK, 2007.
  3. M. R. Turner and A. Al-Chalabi, “Clinical phenotypes,” in The Motor Neurone Disease Handbook, M. Kiernan, Ed., pp. 55–73, Australasian Medical Publishing Company Limited, Prymont, Australia, 2007. View at Google Scholar
  4. B. R. Brooks, “El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis,” Journal of the Neurological Sciences, vol. 124, pp. 96–107, 1994. View at Publisher · View at Google Scholar · View at Scopus
  5. B. R. Brooks, R. G. Miller, M. Swash, and T. L. Munsat, “El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis,” Amyotrophic Lateral Sclerosis, vol. 1, no. 5, pp. 293–299, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Forsgren, B. G. L. Almay, G. Holmgren, and S. Wall, “Epidemiology of motor neuron disease in Northern Sweden,” Acta Neurologica Scandinavica, vol. 68, no. 1, pp. 20–29, 1983. View at Publisher · View at Google Scholar · View at Scopus
  7. F. Khan, L. Turner-Stokes, L. Ng, and T. Kilpatrick, “Multidisciplinary rehabilitation for adults with multiple sclerosis,” Cochrane Database of Systematic Reviews, no. 2, Article ID CD006036, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Greener and P. Langhorne, “Systematic reviews in rehabilitation for stroke: issues and approaches to addressing them,” Clinical Rehabilitation, vol. 16, no. 1, pp. 69–74, 2002. View at Publisher · View at Google Scholar · View at Scopus
  9. L. Turner-Stokes, N. Sykes, E. Silbert, A. Khatri, L. Sutton, and E. Young, “From diagnosis to death: exploring the interface between neurology, rehabilitation and palliative care in the management of people with long term neurological conditions,” Clinical Medicine, vol. 7, no. 2, pp. 129–136, 2007. View at Google Scholar
  10. O. Hardiman, “Multidisciplinary care in motor neurone disease,” in The Motor Neurone Disease Handbook, M. Kiernan, Ed., Australasian Medical Publishing Company, Pyrmont, Australia, 2007. View at Google Scholar
  11. D. Oliver, “Palliative care for motor neurone disease,” Practical Neurology, vol. 2, no. 2, pp. 68–79, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Ng, F. Khan, and S. Mathers, “Multidisciplinary care for adults with amyotrophic lateral sclerosis or motor neuron disease,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD007425, 2009. View at Google Scholar · View at Scopus
  13. B. J. Traynor, M. Alexander, B. Corr, E. Frost, and O. Hardiman, “Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996–2000,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 74, no. 9, pp. 1258–1261, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. J. P. van den Berg, S. Kalmijn, E. Lindeman et al., “Multidisciplinary ALS care improves quality of life in patients with ALS,” Neurology, vol. 65, no. 8, pp. 1264–1267, 2005. View at Publisher · View at Google Scholar · View at Scopus
  15. I. van der Steen, J. P. van den Berg, E. Buskens, E. Lindeman, and L. H. van den Berg, “The costs of amyotrophic lateral sclerosis, according to type of care,” Amyotrophic Lateral Sclerosis, vol. 10, no. 1, pp. 27–34, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Zoccolella, E. Beghi, G. Palagano et al., “Riluzole and amyotrophic lateral sclerosis survival: a population-based study in southern Italy,” European Journal of Neurology, vol. 14, no. 3, pp. 262–268, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Chiò, E. Bottacchi, C. Buffa, R. Mutani, G. Mora, and PARALS, “Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 77, no. 8, pp. 948–950, 2006. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Aridegbe, R. Kandler, S. J. Walters, T. Walsh, P. J. Shaw, and C. J. McDermott, “The natural history of motor neuron disease: assessing the impact of specialist care,” Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, vol. 14, no. 1, pp. 13–19, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. R. G. Miller, C. E. Jackson, E. J. Kasarskis et al., “Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review). Report of the quality standards subcommittee of the American academy of neurology,” Neurology, vol. 73, no. 15, pp. 1218–1226, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. P. M. Andersen, S. Abrahams, G. D. Borasio et al., “EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)—revised report of an EFNS task force,” European Journal of Neurology, vol. 19, no. 3, pp. 360–375, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. P. J. Shaw, “Molecular and cellular pathways of neurodegeneration in motor neurone disease,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 76, no. 6, pp. 1046–1057, 2005. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Cozzolino, A. Ferri, and M. T. Carrì, “Amyotrophic lateral sclerosis: from current developments in the laboratory to clinical implications,” Antioxidants & Redox Signaling, vol. 10, no. 3, pp. 405–443, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. L. C. Wijesekera and P. N. Leigh, “Amyotrophic lateral sclerosis,” Orphanet Journal of Rare Diseases, vol. 4, no. 1, article 3, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. J. D. Rothstein, “Therapeutic horizons for amyotrophic lateral sclerosis,” Current Opinion in Neurobiology, vol. 6, no. 5, pp. 679–687, 1996. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Bensimon, L. Lacomblez, and V. Meininger, “A controlled trial of riluzole in amyotrophic lateral sclerosis,” The New England Journal of Medicine, vol. 330, no. 9, pp. 585–591, 1994. View at Publisher · View at Google Scholar · View at Scopus
  26. L. Lacomblez, G. Bensimon, P. N. Leigh, P. Guillet, and V. Meininger, “Dose-ranging study of riluzole in amyotrophic lateral sclerosis,” The Lancet, vol. 347, no. 9013, pp. 1425–1431, 1996. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Bensimon, L. Lacomblez, J. C. Delumeau, R. Bejuit, P. Truffinet, and V. Meininger, “A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis,” Journal of Neurology, vol. 249, no. 5, pp. 609–615, 2002. View at Publisher · View at Google Scholar · View at Scopus
  28. N. Yanagisawa, K. Tashiro, H. Tohgi et al., “Efficacy and safety of riluzole in patients with amyotrophic lateral sclerosis: double-blind placebo controlled study in Japan,” Igakuno Ayumi, vol. 182, pp. 851–866, 1997. View at Google Scholar
  29. R. G. Miller, J. D. Mitchell, and D. H. Moore, “Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND),” Cochrane Database of Systematic Reviews, 2012. View at Publisher · View at Google Scholar
  30. M. Graf, D. Ecker, R. Horowski et al., “High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study,” Journal of Neural Transmission, vol. 112, no. 5, pp. 649–660, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. V. Palma, V. Bresci, M. Polverino, L. Santoro, and G. Caruso, “An open study of riluzole versus riluzole plus gabapentin in amyotrophic lateral sclerosis,” Journal of the Peripheral Nervous System, vol. 5, no. 1, pp. 46–47, 2000. View at Publisher · View at Google Scholar
  32. P. Caroni, “Activity-sensitive signaling by muscle-derived insulin-like growth factors in the developing and regenerating neuromuscular system,” Annals of the New York Academy of Sciences, vol. 692, pp. 209–222, 1993. View at Publisher · View at Google Scholar · View at Scopus
  33. N. T. Neff, D. Prevette, L. J. Houenou et al., “Insulin-like growth factors: putative muscle-derived trophic agents that promote motoneuron survival,” Journal of Neurobiology, vol. 24, no. 12, pp. 1578–1588, 1993. View at Publisher · View at Google Scholar · View at Scopus
  34. M. Beauverd, J. D. Mitchell, J. H. J. Wokke, and G. D. Borasio, “Recombinant human insulin-like growth factor I (rhIGF-I) for the treatment of amyotrophic lateral sclerosis/motor neuron disease,” Cochrane Database of Systematic Reviews, vol. 11, Article ID CD002064, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. P. Bongioanni, C. Reali, and V. Sogos, “Ciliary neurotrophic factor (CNTF) for amyotrophic lateral sclerosis/motor neuron disease,” Cochrane Database of Systematic Reviews, no. 3, Article ID CD004302, 2004. View at Google Scholar · View at Scopus
  36. R. W. Orrell, R. J. M. Lane, and M. Ross, “Antioxidant treatment for amyotrophic lateral sclerosis or motor neuron disease,” The Cochrane Database of Systematic Reviews, no. 1, Article ID CD002829, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. M. E. Gurney, F. B. Cutting, P. Zhai et al., “Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis,” Annals of Neurology, vol. 39, no. 2, pp. 147–157, 1996. View at Publisher · View at Google Scholar · View at Scopus
  38. J. Knoll, “The pharmacology of selegiline ((-)deprenyl). New aspects,” Acta Neurologica Scandinavica, vol. 80, no. 126, pp. 83–91, 1989. View at Google Scholar · View at Scopus
  39. E. S. Louwerse, G. J. Weverling, P. M. Bossuyt, F. E. Meyjes, and J. M. de Jong, “Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis,” Archives of Neurology, vol. 52, no. 6, pp. 559–564, 1995. View at Publisher · View at Google Scholar · View at Scopus
  40. A. Eisen and C. Krieger, Amyotrophic Lateral Sclerosis: A Synthesis of Research and Clinical Practice, Cambridge University Press, Cambridge, UK, Edited by A. Eisen and C. Krieger, 1998.
  41. M. K. Rafi, A. R. Proctor, C. J. McDermott, and P. J. Shaw, “Respiratory management of motor neurone disease: a review of current practice and new developments,” Practical Neurology, vol. 12, no. 3, pp. 166–176, 2012. View at Publisher · View at Google Scholar · View at Scopus
  42. S. C. Bourke, P. J. Shaw, and G. J. Gibson, “Respiratory function vs sleep-disordered breathing as predictors of QOL in ALS,” Neurology, vol. 57, no. 11, pp. 2040–2044, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. N. Lechtzin, C. M. Wiener, D. M. Shade, L. Clawson, and G. B. Diette, “Spirometry in the supine position improves the detection of diaphragmatic weakness in patients with amyotrophic lateral sclerosis,” Chest, vol. 121, no. 2, pp. 436–442, 2002. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Radunovic, D. Annane, M. K. Rafiq, and N. Mustfa, “Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease,” Cochrane Database of Systematic Reviews, no. 3, Article ID CD004427, 2013. View at Publisher · View at Google Scholar
  45. S. C. Bourke, R. E. Bullock, T. L. Williams, P. J. Shaw, and G. J. Gibson, “Noninvasive ventilation in ALS: indications and effect on quality of life,” Neurology, vol. 61, no. 2, pp. 171–177, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. S. C. Bourke, M. Tomlinson, T. L. Williams, R. E. Bullock, P. J. Shaw, and G. J. Gibson, “Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial,” The Lancet Neurology, vol. 5, no. 2, pp. 140–147, 2006. View at Publisher · View at Google Scholar · View at Scopus
  47. A. Radunovic, D. Annane, K. Jewitt, and N. Mustfa, “Mechanical ventilation for amyotrophic lateral sclerosis/motor neuron disease,” Cochrane Database of Systematic Reviews, no. 7, Article ID CD004427, 2009. View at Google Scholar · View at Scopus
  48. K. A. Kleopa, M. Sherman, B. Neal, G. J. Romano, and T. Heiman-Patterson, “Bipap improves survival and rate of pulmonary function decline in patients with ALS,” Journal of the Neurological Sciences, vol. 164, no. 1, pp. 82–88, 1999. View at Publisher · View at Google Scholar · View at Scopus
  49. A. Pinto, J. P. Almeida, S. Pinto, J. Pereira, A. G. Oliveira, and M. De Carvalho, “Home telemonitoring of non-invasive ventilation decreases healthcare utilisation in a prospective controlled trial of patients with amyotrophic lateral sclerosis,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 81, no. 11, pp. 1238–1242, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. A. Vianello, G. Arcaro, A. Palmieri et al., “Survival and quality of life after tracheostomy for acute respiratory failure in patients with amyotrophic lateral sclerosis,” Journal of Critical Care, vol. 26, no. 3, pp. 329.e7–329.e14, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. L. H. Goldstein, L. Atkins, and P. N. Leigh, “Correlates of quality of life in people with motor neuron disease (MND),” Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, vol. 3, no. 3, pp. 123–129, 2002. View at Publisher · View at Google Scholar · View at Scopus
  52. P. A. Cazzolli and E. A. Oppenheimer, “Home mechanical ventilation for amyotrophic lateral sclerosis: nasal compared to tracheostomy-intermittent positive pressure ventilation,” Journal of the Neurological Sciences, vol. 139, pp. 123–128, 1996. View at Publisher · View at Google Scholar · View at Scopus
  53. A. Kawata, K. Mizoguchi, and H. Hayashi, “A nationwide survey of ALS patients on trachoestomy positive pressure ventilation (TPPV) who developed a totally locked-in state (TLS) in Japan,” Rinsho shinkeigaku, vol. 48, no. 7, pp. 476–480, 2008. View at Google Scholar · View at Scopus
  54. D. S. Tulsky and M. Rosenthal, “Measurement of quality of life in rehabilitation medicine: emerging issues,” Archives of Physical Medicine and Rehabilitation, vol. 84, no. 4, pp. S1–S2, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Hadjikoutis, C. M. Wiles, and R. Eccles, “Cough in motor neuron disease: a review of mechanisms,” QJM, vol. 92, no. 9, pp. 487–494, 1999. View at Publisher · View at Google Scholar · View at Scopus
  56. J. R. Bach, “Amyotrophic lateral sclerosis: prolongation of life by noninvasive respiratory aids,” Chest, vol. 122, no. 1, pp. 92–98, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. J. R. Bach, Y. Ishikawa, and H. Kim, “Prevention of pulmonary morbidity for patients with Duchenne muscular dystrophy,” Chest, vol. 112, no. 4, pp. 1024–1028, 1997. View at Publisher · View at Google Scholar · View at Scopus
  58. M. F. Brito, G. A. Moreira, M. Pradella-Hallinan, and S. Tufik, “Air stacking and chest compression increase peak cough flow in patients with Duchenne muscular dystrophy,” Jornal Brasileiro de Pneumologia, vol. 35, no. 10, pp. 973–979, 2009. View at Google Scholar · View at Scopus
  59. M. Toussaint, L. J. Boitano, V. Gathot, M. Steens, and P. Soudon, “Limits of effective cough-augmentation techniques in patients with neuromuscular disease,” Respiratory Care, vol. 54, no. 3, pp. 359–366, 2009. View at Google Scholar · View at Scopus
  60. T. Hughes, “Neurology of swallowing and oral feeding disorders: assessment and management,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 74, supplement 3, pp. iii48–iii52, 2003. View at Google Scholar · View at Scopus
  61. D. Kidney, M. Alexander, B. Corr, O. O'Toole, and O. Hardiman, “Oropharyngeal dysphagia in amyotrophic lateral sclerosis: neurological and dysphagia specific rating scales,” Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, vol. 5, no. 3, pp. 150–153, 2004. View at Publisher · View at Google Scholar · View at Scopus
  62. J. Skelton, “Nursing role in the multidisciplinary management of motor neurone disease,” British Journal of Nursing, vol. 14, no. 1, pp. 20–24, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. J. C. Desport, P. M. Preux, C. T. Truong, L. Courat, J. M. Vallat, and P. Couratier, “Nutritional assessment and survival in ALS patients,” Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, vol. 1, no. 2, pp. 91–96, 2000. View at Publisher · View at Google Scholar · View at Scopus
  64. P. M. Andersen, G. D. Borasio, R. Dengler et al., “EFNS task force on management of amyotrophic lateral sclerosis: guidelines for diagnosing and clinical care of patients and relatives,” European Journal of Neurology, vol. 12, no. 12, pp. 921–938, 2005. View at Publisher · View at Google Scholar · View at Scopus
  65. P. H. Gordon and H. Mitsumoto, “Symptomatic therapy and palliative aspects of clinical care,” in Handbook of Clinical Neurology, A. A. Eisen and P. J. Shaw, Eds., pp. 389–424, Elsevier, 2007. View at Google Scholar
  66. A. Radunović, H. Mitsumoto, and P. N. Leigh, “Clinical care of patients with amyotrophic lateral sclerosis,” Lancet Neurology, vol. 6, no. 10, pp. 913–925, 2007. View at Publisher · View at Google Scholar · View at Scopus
  67. S. E. Langmore, E. J. Kasarskis, M. L. Manca, and R. K. Olney, “Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease,” Cochrane Database of Systematic Reviews, no. 4, Article ID CD004030, 2006. View at Publisher · View at Google Scholar
  68. A. Chiò, R. Galletti, C. Finocchiaro et al., “Percutaneous radiological gastrostomy: a safe and effective method of nutritional tube placement in advanced ALS,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 75, no. 4, pp. 645–647, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. G. Chavada, A. El-Nayal, F. Lee et al., “Evaluation of two different methods for per-oral gastrostomy tube placement in patients with motor neuron disease (MND): PIG versus PEG procedures,” Amyotrophic Lateral Sclerosis, vol. 11, no. 6, pp. 531–536, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. H.-U. Laasch, L. Wilbraham, K. Bullen et al., “Gastrostomy insertion: comparing the options—PEG, RIG or PIG?” Clinical Radiology, vol. 58, no. 5, pp. 398–405, 2003. View at Publisher · View at Google Scholar · View at Scopus
  71. P. N. Leigh, S. Abrahams, A. Al-Chalabi et al., “The management of motor neurone disease,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 74, supplement 4, pp. iv32–iv47, 2003. View at Google Scholar · View at Scopus
  72. R. A. Lyall, N. Donaldson, M. I. Polkey, P. N. Leigh, and J. Moxham, “Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis,” Brain, vol. 124, no. 10, pp. 2000–2013, 2001. View at Publisher · View at Google Scholar · View at Scopus
  73. J. Rosenfeld and A. Ellis, “Nutrition and dietary supplements in motor neuron disease,” Physical Medicine and Rehabilitation Clinics of North America, vol. 19, no. 3, pp. 573–589, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. F. J. Thornton, T. Fotheringham, M. Alexander, O. Hardiman, F. P. McGrath, and M. J. Lee, “Amyotrophic lateral sclerosis: enteral nutrition provision—endoscopic or radiologic gastrostomy?” Radiology, vol. 224, no. 3, pp. 713–717, 2002. View at Publisher · View at Google Scholar · View at Scopus
  75. A. S. Shaw, M.-A. Ampong, A. Rio et al., “Survival of patients with ALS following institution of enteral feeding is related to pre-procedure oximetry: a retrospective review of 98 patients in a single centre,” Amyotrophic Lateral Sclerosis, vol. 7, no. 1, pp. 16–21, 2006. View at Publisher · View at Google Scholar · View at Scopus
  76. J.-C. Desport, T. Mabrouk, P. Bouillet, A. Perna, P.-M. Preux, and P. Couratier, “Complications and survival following radiologically and endoscopically-guided gastronomy in patients with amyotrophic lateral sclerosis,” Amyotrophic Lateral Sclerosis, vol. 6, no. 2, pp. 88–93, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. H. D. Katzberg and M. Benatar, “Enteral tube feeding for amyotrophic lateral sclerosis/motor neuron disease,” Cochrane Database of Systematic Reviews, vol. 1, Article ID CD004030, 2011. View at Google Scholar · View at Scopus
  78. A. Verschueren, A. Monnier, S. Attarian, D. Lardillier, and J. Pouget, “Enteral and parenteral nutrition in the later stages of ALS: an observational study,” Amyotrophic Lateral Sclerosis, vol. 10, no. 1, pp. 42–46, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. A.-M. Wills, J. Hubbard, E. A. Macklin et al., “Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial,” The Lancet, vol. 383, no. 9934, pp. 2065–2072, 2014. View at Publisher · View at Google Scholar · View at Scopus
  80. C. E. Jackson, G. Gronseth, J. Rosenfeld et al., “Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients,” Muscle & Nerve, vol. 39, no. 2, pp. 137–143, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. J. Costa, M. L. Rocha, J. Ferreira, T. Evangelista, M. Coelho, and M. De Carvalho, “Botulinum toxin type-B improves sialorrhea and quality of life in bulbaronset amyotrophic lateral sclerosis,” Journal of Neurology, vol. 255, no. 4, pp. 545–550, 2008. View at Publisher · View at Google Scholar · View at Scopus
  82. S. Peysson, N. Vandenberghe, F. Philit et al., “Factors predicting survival following noninvasive ventilation in amyotrophic lateral sclerosis,” European Neurology, vol. 59, no. 3-4, pp. 164–171, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. J. P. Gallagher, “Pathologic laughter and crying in ALS: a search for their origin,” Acta Neurologica Scandinavica, vol. 80, no. 2, pp. 114–117, 1989. View at Publisher · View at Google Scholar · View at Scopus
  84. A. Szczudlik, A. Słowik, and B. Tomik, “The effect of amitriptyline on the pathological crying and other pseudobulbar signs,” Neurologia i Neurochirurgia Polska, vol. 29, no. 5, pp. 663–674, 1995. View at Google Scholar · View at Scopus
  85. S. Iannaccone and L. Ferini-Strambi, “Pharmacologic treatment of emotional lability,” Clinical Neuropharmacology, vol. 19, no. 6, pp. 532–535, 1996. View at Publisher · View at Google Scholar · View at Scopus
  86. E. P. Pioro, B. R. Brooks, J. Cummings et al., “Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect,” Annals of Neurology, vol. 68, no. 5, pp. 693–702, 2010. View at Publisher · View at Google Scholar
  87. R. G. Miller, C. E. Jackson, E. J. Kasarskis et al., “Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology,” Neurology, vol. 73, no. 15, pp. 1218–1226, 2009. View at Publisher · View at Google Scholar · View at Scopus
  88. R. S. Bedlack, D. M. Pastula, J. Hawes, and D. Heydt, “Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease,” Amyotrophic Lateral Sclerosis, vol. 10, no. 4, pp. 210–215, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. H. D. Katzberg, A. H. Khan, and Y. T. So, “Assessment: symptomatic treatment for muscle cramps (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology,” Neurology, vol. 74, no. 8, pp. 691–696, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. V. E. Drory, E. Goltsman, J. Goldman Reznik, A. Mosek, and A. D. Korczyn, “The value of muscle exercise in patients with amyotrophic lateral sclerosis,” Journal of the Neurological Sciences, vol. 191, no. 1-2, pp. 133–137, 2001. View at Publisher · View at Google Scholar · View at Scopus
  91. S. McClelland III, F. A. Bethoux, N. M. Boulis et al., “Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief,” Muscle & Nerve, vol. 37, no. 3, pp. 396–398, 2008. View at Publisher · View at Google Scholar · View at Scopus
  92. G. T. Carter and R. G. Miller, “Comprehensive management of amyotrophic lateral sclerosis,” Physical Medicine and Rehabilitation Clinics of North America, vol. 9, no. 1, pp. 271–284, 1998. View at Google Scholar · View at Scopus
  93. J.-S. Lou, “Fatigue in amyotrophic lateral sclerosis,” Physical Medicine and Rehabilitation Clinics of North America, vol. 19, no. 3, pp. 533–543, 2008. View at Publisher · View at Google Scholar · View at Scopus
  94. G. T. Carter, M. D. Weiss, J.-S. Lou et al., “Modafinil to treat fatigue in amyotrophic lateral sclerosis: an open label pilot study,” American Journal of Hospice and Palliative Medicine, vol. 22, no. 1, pp. 55–59, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. J. G. Rabkin, P. H. Gordon, M. Mcelhiney, R. Rabkin, S. Chew, and H. Mitsumoto, “Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study,” Muscle and Nerve, vol. 39, no. 3, pp. 297–303, 2009. View at Publisher · View at Google Scholar · View at Scopus
  96. P. H. Gordon, B. Cheng, I. B. Katz et al., “The natural history of primary lateral sclerosis,” Neurology, vol. 66, no. 5, pp. 647–653, 2006. View at Publisher · View at Google Scholar · View at Scopus
  97. M. Cobble, “Language impairment in motor neurone disease,” Journal of the Neurological Sciences, vol. 160, no. 1, pp. S47–S52, 1998. View at Publisher · View at Google Scholar · View at Scopus
  98. G. D. Borasio, R. Voltz, and R. G. Miller, “Palliative care in amyotrophic lateral sclerosis,” Neurologic Clinics, vol. 19, no. 4, pp. 829–847, 2001. View at Publisher · View at Google Scholar · View at Scopus
  99. K. E. Steinhauser, N. A. Christakis, E. C. Clipp, M. McNeilly, L. McIntyre, and J. A. Tulsky, “Factors considered important at the end of life by patients, family, physicians, and other care providers,” Journal of the American Medical Association, vol. 284, no. 19, pp. 2476–2482, 2000. View at Publisher · View at Google Scholar · View at Scopus
  100. D. R. Rosen, T. Siddique, D. Patterson et al., “Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis,” Nature, vol. 362, no. 6415, pp. 59–62, 1993. View at Google Scholar · View at Scopus
  101. A. Yokoseki, A. Shiga, C.-F. Tan et al., “TDP-43 mutation in familial amyotrophic lateral sclerosis,” Annals of Neurology, vol. 63, no. 4, pp. 538–542, 2008. View at Publisher · View at Google Scholar · View at Scopus
  102. J. Sreedharan, I. P. Blair, V. B. Tripathi et al., “TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis,” Science, vol. 319, no. 5870, pp. 1668–1672, 2008. View at Publisher · View at Google Scholar · View at Scopus
  103. E. Kabashi, P. N. Valdmanis, P. Dion et al., “TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis,” Nature Genetics, vol. 40, no. 5, pp. 572–574, 2008. View at Publisher · View at Google Scholar · View at Scopus
  104. S. Hadano, C. K. Hand, H. Osuga et al., “A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2,” Nature Genetics, vol. 29, no. 2, pp. 166–173, 2001. View at Publisher · View at Google Scholar
  105. Y. Yang, A. Hentati, H. X. Deng et al., “The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis,” Nature Genetics, vol. 29, no. 2, pp. 160–165, 2001. View at Publisher · View at Google Scholar
  106. Y.-Z. Chen, C. L. Bennett, H. M. Huynh et al., “DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral sclerosis (ALS4),” The American Journal of Human Genetics, vol. 74, no. 6, pp. 1128–1135, 2004. View at Publisher · View at Google Scholar · View at Scopus
  107. A. L. Nishimura, M. Mitne-Neto, H. C. A. Silva et al., “A mutation in the vesicle-trafficking protein VAPB causes late-onset spinal muscular atrophy and amyotrophic lateral sclerosis,” American Journal of Human Genetics, vol. 75, no. 5, pp. 822–831, 2004. View at Publisher · View at Google Scholar · View at Scopus
  108. M. J. Greenway, M. D. Alexander, S. Ennis et al., “A novel candidate region for ALS on chromosome 14q11.2,” Neurology, vol. 63, no. 10, pp. 1936–1938, 2004. View at Publisher · View at Google Scholar · View at Scopus
  109. M. J. Greenway, P. M. Andersen, G. Russ et al., “ANG mutations segregate with familial and 'sporadic' amyotrophic lateral sclerosis,” Nature Genetics, vol. 38, no. 4, pp. 411–413, 2006. View at Publisher · View at Google Scholar · View at Scopus
  110. I. Puls, C. Jonnakuty, B. H. LaMonte et al., “Mutant dynactin in motor neuron disease,” Nature Genetics, vol. 33, no. 4, pp. 455–456, 2003. View at Publisher · View at Google Scholar · View at Scopus
  111. C. Münch, R. Sedlmeier, T. Meyer et al., “Point mutations of the p150 subunit of dynactin (DCTN1) gene in ALS,” Neurology, vol. 63, no. 4, pp. 724–726, 2004. View at Publisher · View at Google Scholar · View at Scopus
  112. A. Al-Chalabi, Z. E. Enayat, M. C. Bakker et al., “Association of apolipoprotein E ε4 allele with bulbar-onset motor neuron disease,” The Lancet, vol. 347, no. 8995, pp. 159–160, 1996. View at Publisher · View at Google Scholar · View at Scopus
  113. T. Meyer, A. Fromm, C. Münch et al., “The RNA of the glutamate transporter EAAT2 is variably spliced in amyotrophic lateral sclerosis and normal individuals,” Journal of the Neurological Sciences, vol. 170, no. 1, pp. 45–50, 1999. View at Publisher · View at Google Scholar · View at Scopus
  114. D. Trotti, M. Aoki, P. Pasinelli et al., “Amyotrophic lateral sclerosis-linked glutamate transporter mutant has impaired glutamate clearance capacity,” The Journal of Biological Chemistry, vol. 276, no. 1, pp. 576–582, 2001. View at Publisher · View at Google Scholar · View at Scopus
  115. D. Lambrechts, E. Storkebaum, M. Morimoto et al., “VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death,” Nature Genetics, vol. 34, no. 4, pp. 383–394, 2003. View at Publisher · View at Google Scholar · View at Scopus
  116. P. Pasinelli and R. H. Brown, “Molecular biology of amyotrophic lateral sclerosis: insights from genetics,” Nature Reviews Neuroscience, vol. 7, no. 9, pp. 710–723, 2006. View at Publisher · View at Google Scholar · View at Scopus
  117. L. Siklós, J. Engelhardt, Y. Harati, R. G. Smith, F. Joó, and S. H. Appel, “Ultrastructural evidence for altered calcium in motor nerve terminals in amyotrophic lateral sclerosis,” Annals of Neurology, vol. 39, no. 2, pp. 203–216, 1996. View at Publisher · View at Google Scholar · View at Scopus
  118. F. R. Wiedemann, K. Winkler, A. V. Kuznetsov et al., “Impairment of mitochondrial function in skeletal muscle of patients with amyotrophic lateral sclerosis,” Journal of the Neurological Sciences, vol. 156, no. 1, pp. 65–72, 1998. View at Publisher · View at Google Scholar · View at Scopus
  119. T. L. Williamson and D. W. Cleveland, “Slowing of axonal transport is a very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons,” Nature Neuroscience, vol. 2, no. 1, pp. 50–56, 1999. View at Publisher · View at Google Scholar · View at Scopus
  120. T. Murakami, I. Nagano, T. Hayashi et al., “Impaired retrograde axonal transport of adenovirus-mediated E. coli LacZ gene in the mice carrying mutant SOD1 gene,” Neuroscience Letters, vol. 308, no. 3, pp. 149–152, 2001. View at Publisher · View at Google Scholar · View at Scopus
  121. K. J. De Vos, A. J. Grierson, S. Ackerley, and C. C. J. Miller, “Role of axonal transport in neurodegenerative diseases,” Annual Review of Neuroscience, vol. 31, pp. 151–173, 2008. View at Publisher · View at Google Scholar · View at Scopus
  122. S. Carpenter, “Proximal axonal enlargement in motor neuron disease,” Neurology, vol. 18, no. 9, pp. 841–851, 1968. View at Publisher · View at Google Scholar · View at Scopus
  123. A. Hirano, I. Nakano, L. T. Kurland, D. W. Mulder, P. W. Holley, and G. Saccomanno, “Fine structural study of neurofibrillary changes in a family with amyotrophic lateral sclerosis,” Journal of Neuropathology and Experimental Neurology, vol. 43, no. 5, pp. 471–480, 1984. View at Publisher · View at Google Scholar · View at Scopus
  124. P. Anand, A. Parrett, J. Martin et al., “Regional changes of ciliary neurotrophic factor and nerve growth factor levels in post mortem spinal cord and cerebral cortex from patients with motor disease,” Nature Medicine, vol. 1, no. 2, pp. 168–172, 1995. View at Publisher · View at Google Scholar · View at Scopus
  125. J. L. Elliott and W. D. Snider, “Motor neuron growth factors,” Neurology, vol. 47, no. 4, supplement 2, pp. S47–S53, 1996. View at Publisher · View at Google Scholar · View at Scopus
  126. R. W. Oppenheim, “Neurotrophic survival molecules for motoneurons: an embarrassment of riches,” Neuron, vol. 17, no. 2, pp. 195–197, 1996. View at Publisher · View at Google Scholar · View at Scopus
  127. C. Guégan and S. Przedborski, “Programmed cell death in amyotrophic lateral sclerosis,” Journal of Clinical Investigation, vol. 111, no. 2, pp. 153–161, 2003. View at Publisher · View at Google Scholar · View at Scopus
  128. P. Pasinelli, D. R. Borchelt, M. K. Houseweart, D. W. Cleveland, and R. H. Brown Jr., “Caspase-1 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper-zinc superoxide dismutase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 95, no. 26, pp. 15763–15768, 1998. View at Publisher · View at Google Scholar · View at Scopus
  129. P. Pasinelli, M. K. Houseweart, R. H. Brown Jr., and D. W. Cleveland, “Caspase-1 and -3 are sequentially activated in motor neuron death in Cu,Zn superoxide dismutase-mediated familial amyotrophic lateral sclerosis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 25, pp. 13901–13906, 2000. View at Publisher · View at Google Scholar · View at Scopus